In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PowderMed's Vaccines: Out of Chiron, Into the Clinic

Executive Summary

The £542 million ($959 million) that Chiron Corp. spent acquiring PowderJect Pharmaceuticals PLC in mid-2003 was a move by the US company to get its hands on PowderJect's thriving Fluvirin influenza vaccine business and, oddly enough, bulk up its infrastructure on its home soil.

You may also be interested in...



Pfizer's PowderMed Purchase Buoys VCs, Vaccines

Pfizer's October 2006 acquisition of DNA-vaccine specialist PowderMed was the largest ever acquisition of a UK biotech. PowderMed's investors saw a solid return on the deal, which underscored Big Pharma's rush to spread their bets on next-generation large-molecule platforms.

Cancer Vaccines: European Immunotherapy Strategies

European developers of therapeutic cancer vaccines are making steady, if slow progress towards clinical and regulatory success. But late-stage setbacks and delays at North American firms-which are several years more advanced and thus bearing the brunt of working out the regulatory kinks-highlight the challenges associated with bringing a cancer vaccine to market. Given the various technological and commercial approaches to immunotherapy on either side of the ocean, European firms are closely watching the progress of similar technologies in the US.

Chiron/PowderJect: US Snaps Up Europe's Best

Chiron's acquisition of PowderJect is the most recent sign that the vaccines industry is coming of age, taking the field's only two mid-sized players up among the top-ranking Big Pharma. This deal was largely about infrastructure. But it suggests any European biotech with a valuable asset--be it product or distribution network--is an attractive takeover target for US firms.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel